PCI Biotech Holding is developing a light-directed drug delivery system with the potential to make drug delivery more efficient and targeted, and to reduce overall toxicity. The company's technology is based on the fact that cells absorb molecules, including proteins and other biological macromolecules, drug carriers such as antibodies and nanoparticles, and some small molecules, by engulfing them with the cell membrane, in a process called endocytosis. This creates an endosome, a small "bubble" of cell membrane enclosing the absorbed molecules. For the biologically active molecules to interact with the intracellular targets, they must be released from the endosome into the cytosol in a process called "endosomal escape."
Hoffsveien 48
N-0377 Oslo, Norway
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.
Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.
AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.
